Innate Pharma S.A. (LON:0EVI)
London flag London · Delayed Price · Currency is GBP · Price in EUR
1.500
-0.020 (-1.32%)
At close: Jul 11, 2025

Innate Pharma Revenue

In the year 2024, Innate Pharma had annual revenue of 20.12M EUR, down -67.36%. Innate Pharma had revenue of 7.78M in the half year ending December 31, 2024, a decrease of -35.66%.

Revenue
20.12M EUR
Revenue Growth
-67.36%
P/S Ratio
7.09
Revenue / Employee
111.17K EUR
Employees
181
Market Cap
118.02M GBP

Revenue Chart

* This company reports financials in EUR.

Revenue History

Fiscal Year End Revenue Change Growth
Dec 31, 2024 20.12M -41.52M -67.36%
Dec 31, 2023 61.64M 3.97M 6.88%
Dec 31, 2022 57.67M 32.97M 133.47%
Dec 31, 2021 24.70M -45.07M -64.60%
Dec 31, 2020 69.77M -15.68M -18.35%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
AstraZeneca 42.56B
HSBC Holdings 44.89B
Shell 217.54B
Unilever 50.25B
British American Tobacco p.l.c. 25.87B
Rolls-Royce Holdings 18.91B
Rio Tinto Group 42.86B
RELX PLC 9.43B
Revenue Rankings